Spinal Muscular Atrophy Treatment Market-Forecast to 2026
According to a new market research report published by Global Market Estimates, the Global Spinal Muscular Atrophy Treatment Market is projected to grow from USD 1.91 billion in 2021 to USD 15.01 billion by 2026 at a CAGR value of 30.6% from 2021 to 2026. The increasing incidence of spinal muscular atrophy, degenerative illnesses, and extensive awareness regarding SMA diagnoses and therapy amongst healthcare providers across the globe, the SMA treatment market is expected to increase exponentially.
Browse 151 Market Data Tables and 111 Figures spread through 181 Pages and in-depth TOC on “Global Spinal Muscular Atrophy Treatment Market Forecast to 2026" https://www.globalmarketestimates.com/market-report/spinal-muscular-atrophy-treatmentmarket-3625
By Type (Type I, Type II, Type III and Type IV), By Treatment (Gene Replacement Therapy and Drug Therapy), By Route of Administration (Oral, Intrathecal and Others), By Distribution Channel (Hospitals & Clinics, Pharmacies, Drug stores, Others), Company Market Share Analysis, and Competitor Analysis
Key Market Insights
As per the type outlook, Type I system segment is expected to have the largest share in the market The drug therapy segment is expected to have the largest share in the market owing to enhanced focus on the targeted or afflicted cells as per treatment outlook The market for the intrathecal segment (as per route of administration outlook) is estimated to have the largest share during the forecast period of 2021 to 2026 As per the end-user outlook, the hospitals & clinics segment is anticipated to have the largest share PTC Therapeutics, Biogen, Voyager Therapeutics, Inc., Astellas Pharma Inc., Novartis AG, Pfizer, Inc., F. Hoffmann-La Roche Ltd, Cytokinetics, Inc., Ionis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc, among others, are the key players in the spinal muscular atrophy treatment market.